ICCC
IMMUCELL CORP /DE/
Key Financials
Net Income
$-1040027
↑ 51.8%
Revenue
$27.6M
↑ 4.3%
Gross Profit
$11.4M
↑ 44.1%
Operating Income
$1.6M
↑ 200.6%
EPS (Diluted)
$-0.12
↑ 53.8%
Total Assets
$42.5M
↓ 5.7%
Shareholders' Equity
$27.1M
↓ 1.7%
Total Liabilities
$15.5M
↓ 12.0%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 8-K | 5/14/2026 | View on SEC |
| 10-Q | 5/14/2026 | View on SEC |
| 10-K/A | 5/13/2026 | View on SEC |
| 8-K | 5/8/2026 | View on SEC |
| DEF 14A | 4/24/2026 | View on SEC |
| 3 | 4/23/2026 | View on SEC |
| 3 | 4/23/2026 | View on SEC |
| 4 | 4/16/2026 | View on SEC |
| 4 | 4/16/2026 | View on SEC |
| 4 | 4/16/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | ICCC |
| Company Name | IMMUCELL CORP /DE/ |
| CIK | 811641 |
| Sector | In Vitro & In Vivo Diagnostic Substances |
| Industry | Non-accelerated filer Smaller reporting company |
| Exchange | Nasdaq |
| SIC Code | 2835 |
| SIC Description | In Vitro & In Vivo Diagnostic Substances |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 2078782770 |